Cheng L Liu

US Patent:

7239488, Jul 3, 2007

Filed:

Mar 9, 2004

Appl. No.:

10/797653

Inventors:

Li-Yan Zhu - San Jose CA, US
Kazumasa Yasuda - Sunnyvale CA, US
Cheng Yih Liu - San Jose CA, US
Winston Jose - San Jose CA, US

Assignee:

SAE Magnetics (H.K.), Ltd. - Shatin, N.T.

International Classification:

G11B 5/127
G11B 21/21
G11B 5/39

US Classification:

360323, 3602353, 2960314

Abstract:

According to an embodiment of the present invention, a slider design is presented that provides improved protection for the head/sensor of the slider. In one embodiment, the design of the slider is such that ESD protection is provided during the slider wafer process, the “back-end” processes (e. g. , when the completed slider/head is incorporated into an HGA), and during operation in a disk drive or the like. In this embodiment, a conductive film is provided that surrounds the insulating-material slider substrate. The conductive film provides a grounding path during the wafer fabrication processes. This conductive layer may be further patterned during head fabrication to provide a ground path for back-end fabrication processes. A conductive stripe may be added for discharging debris in the slider-to-disk interface.

US Patent:

8526913, Sep 3, 2013

Filed:

Oct 8, 2012

Appl. No.:

13/647019

Inventors:

Richard Kuo - Mountain View CA, US
Cheng P Liu - Duluth GA, US

Assignee:

AT&T Intellectual Property I, L.P. - Atlanta GA

International Classification:

H04M 1/66

US Classification:

455410, 455411, 4554351

Abstract:

Systems, methods, and computer program products are for managing access to a femtocell coverage area. An exemplary method includes storing in a memory component a first identifier corresponding to a subscribed service of a communication device and a second identifier corresponding to a user of the communication device, and granting access to the femtocell coverage area using the second identifier.

US Patent:

20090155821, Jun 18, 2009

Filed:

Jan 4, 2007

Appl. No.:

12/159827

Inventors:

John Kunich - San Leandro CA, US
Cheng Liu - Richmond CA, US

International Classification:

G01N 33/574
G01N 33/566

US Classification:

435 723, 435 72

Abstract:

Methods for detecting antibody dependent cellular cytotoxicity (ADCC) are described herein. The methods are label-free, and can be performed in real time on adherent cells. The methods can include, for example, (a) monitoring the impedance between electrodes on a non-conducting substrate that supports the growth of target cells in an assay medium; and (b) adding effector cells and an antibody that binds to the target cells to the assay medium; wherein any decrease in the impedance between the electrodes on the substrate following addition of the effector cells and the antibody is indicative of ADCC function having been effected in the assay medium.

US Patent:

20090265142, Oct 22, 2009

Filed:

Apr 17, 2009

Appl. No.:

12/426092

Inventors:

Cheng Liu - Fremont CA, US
Gayle L. Noble - Boulder Creek CA, US
Lucy G. Hosking - Santa Cruz CA, US
Luke M. Ekkizogloy - San Jose CA, US

Assignee:

FINISAR CORPORATION - Sunnyvale CA

International Classification:

G06F 15/00

US Classification:

702190

Abstract:

One example embodiment includes a testing device. The testing device comprises a signal reception element, an out-of-band detector and testing logic. The signal reception element is configured to receive a physical layer signal from a communication module via a physical link and to produce an incoming double modulated signal, the incoming double modulated signal including a high-speed data signal and an out-of-band data signal. The out-of-band data signal comprises diagnostic data of the communication module. The out-of-band detector is coupled to the signal reception element and is configured to extract the out-of-band data signal from the incoming double modulated signal. The testing logic is coupled to the out-of-band detector and is configured to extract and analyze the diagnostic data from the out-of-band data signal.

US Patent:

20230065527, Mar 2, 2023

Filed:

Aug 12, 2021

Appl. No.:

17/444947

Inventors:

- South San Francisco CA, US
Pierre Jean-Marie Bernard Raboisson - Wavre, BE
Francois Gonzalvez - Antwerp, BE
Antitsa Dimitrova Stoycheva - Half Moon Bay CA, US
Jerome Deval - Pacifica CA, US
Cheng Liu - Burlingame CA, US
Qingling Zhang - Emerald Hills CA, US

International Classification:

C07D 487/10
C07D 519/00
C07D 401/14
C07D 491/107
C07D 491/048
C07D 471/04

Abstract:

The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

US Patent:

20230031213, Feb 2, 2023

Filed:

Jun 15, 2022

Appl. No.:

17/807083

Inventors:

- South San Francisco CA, US
Pierre Jean-Marie Bernard Raboisson - Wavre, BE
Francois Gonzalvez - Antwerp, BE
Antitsa Dimitrova Stoycheva - Half Moon Bay CA, US
Cheng Liu - Burlingame CA, US
Jerome Deval - Pacifica CA, US
David McGowan - Brussels, BE

International Classification:

C07D 401/14
C07D 491/048
C07D 487/10
C07D 405/14
C07D 403/12
C07D 401/12
C07D 498/10
C07D 471/04
C07D 519/00
C07D 413/14

Abstract:

The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

US Patent:

20230002413, Jan 5, 2023

Filed:

May 19, 2021

Appl. No.:

17/303089

Inventors:

- South San Francisco CA, US
Pierre Jean-Marie Bernard Raboisson - Wavre, FR
Antitsa Dimitrova Stoycheva - Half Moon Bay CA, US
Francois Gonzalvez - Antwerp, BE
Jerome Deval - Pacifica CA, US
Cheng Liu - Burlingame CA, US

International Classification:

C07D 519/00
C07C 229/16
C07C 215/14
C07C 233/36
C07D 207/267
C07D 295/135
C07D 217/02
C07D 209/44
C07C 211/42
C07D 205/12
C07D 491/107
C07D 217/04
C07D 401/14
C07D 471/04

Abstract:

The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

US Patent:

20210093666, Apr 1, 2021

Filed:

Apr 24, 2018

Appl. No.:

16/608362

Inventors:

- Emeryville CA, US
Fei XIE - San Mateo CA, US
Yiyang XU - Pleasanton CA, US
Hong LIU - El Sobrante CA, US
Cheng LIU - Emeryville CA, US

International Classification:

A61K 35/17
C07K 16/28
C07K 16/30
C07K 14/725

Abstract:

The present application provides immune cells (such as T cells) comprising a chimeric antibody-T cell receptor (TCR) construct (caTCR) and a secretory secondary effector (SSE) construct. The caTCR comprises an antigen-binding module that specifically binds to a target antigen and a T cell receptor module (TCRM) capable of recruiting at least one TCR-associated signaling molecule, and the SSE is capable of enhancing an immune response mediated by the caTCR. Also provided are methods of making and using these cells.